Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity-Reference-Cited by-同舟云学术

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

Published:2019-08 Issue:8 Volume:26 Page:1067-1080.e8
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Hafner Marc^ORCID,Mills Caitlin E.,Subramanian Kartik,Chen Chen,Chung Mirra,Boswell Sarah A.,Everley Robert A.,Liu Changchang,Walmsley Charlotte S.,Juric Dejan,Sorger Peter K.

Funder

National Institutes of Health/National Cancer Institute

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference76 articles.

1. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity;Anastassiadis;Nat. Biotechnol.,2011

2. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat. Rev. Drug Discov.,2015

3. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer;Asghar;Clin. Cancer Res.,2017

4. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets;Balko;Cancer Discov.,2014

5. A probability-based approach for high-throughput protein phosphorylation analysis and site localization;Beausoleil;Nat. Biotechnol.,2006

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant;Cancer Cell;2024-09

3. Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer;Breast Cancer: Targets and Therapy;2024-08

4. Exploring the Single-Cell Dynamics of FOXM1 Under Cell Cycle Perturbations;2024-07-28

5. Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery;Expert Opinion on Drug Discovery;2024-07-14